Clinical trial
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
NCT00083343 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00083343 |
|---|---|
| Title | Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) |
| Official title | A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections (Excluding Patients With Candidemia as the Sole Site of Infection) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Candidiasis |
| Intervention type | Drug |
| Interventions | MK0991, caspofungin acetate/Duration of Treatment: variable |
| Enrollment | 48 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | May 24, 2004 |
| Last update posted | Feb 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: